This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
ADSTILADRIN
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
NRG-GU 0101
Masofaniten (EPI-7386)
METANOVA
RTIRE
SHORTER
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SESAUA 2024
Southern CA GU Cancer Research Forum 2024
AUA Urology Advocacy Summit 2024
ASCO GU 2024
2024 UCSF-UCLA PSMA Conference
SUO 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
2019 International Bladder Cancer Network
Viewing 1-20 of 24 articles
IBCN 2019: Transcriptomic Profiling of Bladder Cancer
IBCN 2019: Association of Immunohistochemical Markers Molecular Subtypes in Bladder Cancer
IBCN 2019: Genomic Classifier to Predict Luminal Bladder Tumors
IBCN 2019: Immunological Tumor Microenvironment in Patients with Muscle Invasive Bladder Cancer Treated with Radical Cystectomy
IBCN 2019: Transcriptomic Data from a Cohort of Neuroendocrine Bladder Cancer Variant Histology Patients
IBCN 2019: Twenty-Year Experience of Outcomes from the Swedish National Registry of Urinary Bladder Cancer
IBCN 2019: Neoadjuvant Atezolizumab for cT2-4 N0 M0 Muscle-Invasive Bladder Cancer, A Phase II Trial
IBCN 2019: Non-Cisplatin Based Neoadjuvant Chemotherapy Agents for Cisplatin-Ineligible Patients Prior to Radical Cystectomy
IBCN 2019: The BLASST-1 Phase II Trial, the Efficacy and Safety of Nivolumab with Gemcitabine-Cisplatin - A Neoadjuvant Option for Patients with MIBC
IBCN 2019: Topography Analysis from Multispectral Imaging of the Immune Landscape in Bladder Cancer FFPE Specimens
IBCN 2019: Platinum-Based Neoadjuvant Chemotherapy on the Bladder Tumor Microenvironment
IBCN 2019: Molecular Subtyping in Patients with Muscle Invasive Bladder Cancer
IBCN 2019: Neoadjuvant Cisplatin-Based Chemotherapy on T Cell Phenotypes within the Sentinel Nodes of MIBC Patients
IBCN 2019: Multicenter Validation Study of Histopathologic “Tumor Regression Grading” Following Neoadjuvant Therapy for Muscle Invasive Bladder Cancer
IBCN 2019: FGFR3 Mutations Investigated In an In Vivo Murine Model
IBCN 2019: Muscle-Invasive Bladder Cancer Novel Mouse Model Capable of Orthotopic Transplantation
IBCN 2019: TERT Promoter Mutations in Low-Grade Bladder Cancer Carcinogenesis
IBCN 2019: Molecular Characterization of Normal Ureteric Urothelium for More Meaningful Comparisons with Bladder Urothelium
IBCN 2019: The Synergistic Potential of BCG and STING Pathway Activators to Improve Response of Non-Muscle Invasive Bladder Cancer
IBCN 2019: Advanced Pathologic T1 Substaging to Improve the Identification of High-Risk Non-muscle Invasive Bladder Cancer Patients at Risk for BCG-Failure
1
2
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free